TherOx AO System: hyperoxemic perfusion for the treatment of microvascular ischaemia in patients with acute myocardial infarction

Mundy L, Merlin T, Braunack-Mayer A, Hiller J
Record ID 32006000638
Authors' recommendations: In summary, the TherOx® aqueous oxygen (AO) system appears to be effective in increasing the left ventricular ejection fraction and decreasing the wall motion score index when compared to standard treatment alone, for patients presenting within 24 hours of acute myocardial infarction (AMI) symptom onset. Both of these factors indicate improved left ventricular function. These improvements are greater for patients who are treated within six hours of AMI symptom onset. However, follow-up was short-term (3 months) in the studies included in this assessment. What the improvement in left ventricular ejection fraction (LVEF) and wall motion score indexes (WMSI) mean for patient survival in the long term is unclear. It is also unclear from these studies what the effect of AO treatment would be for patients who present late with symptoms of AMI. In addition, the number of patients reported on in the two peer reviewed studies are quite small considering the large patient group that would be available for treatment of this kind (n=29; 24 patients treated with AO). It would be prudent to await the complete results of the Acute Myocardial Infarction Hyperbaric Oxygen Treatment (AMIHOT) trial, which are expected in late 2005. There are currently no cost-effectiveness data available for the utilisation of the TherOx® AO system. At this present moment in time there is no evidence to suggest that treatment with AO reduces the amount of time spent in hospital after AMI. However, treatment with AO may reduce the extent of left ventricular (LV) injury, the number of re-infarctions or recurrent ischaemia, and in so doing may reduce the overall costs of AMI on the health system.
Project Status: Completed
Year Published: 2005
URL for published report: Not Available
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Australia
MeSH Terms
  • Infusions, Intra-Arterial
  • Myocardial Reperfusion
  • Coronary Circulation
  • Myocardial Infarction
  • Myocardial Ischemia
  • Oxygen
Organisation Name: Adelaide Health Technology Assessment
Contact Address: School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617
Contact Name:
Contact Email:
Copyright: Adelaide Health Technology Assessment (AHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.